Tomonori Ishii

Featured in: Favicon

biomedcentral.com Favicon

jrheum.org Favicon

clinicaltherapeutics.com Favicon

onlinelibrary.wiley.com Favicon

ard.bmj.com Favicon

arthritis-research.biomedcentral.com

Articles

Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus Erythematosus

Apr 27, 2024 | medrxiv.org | Yoshiya Tanaka |Atsushi Kumanogoh |Tatsuya Atsumi |Tomonori Ishii

COMPETING INTERESTS: YT has received grants from Mitsubishi-Tanabe, Eisai, Chugai, and Taisho; speaker fees and/or honoraria from Eli Lilly, AstraZeneca, Abbvie, Gilead, Chugai, Behringer-Ingelheim, GlaxoSmithKline, Eisai, Taisho, Bristol-Myers Squibb, Pfizer, and Taiho. AK has received grants from Chugai; consulting fees from Eisai; speaker fees and/or honoraria from Asahi Kasei, Astellas, Eisai, GlaxoSmithKline, Chugai, Eli Lilly, Boehringer-Ingelheim, Pfizer, and Bristol-Myers Squibb.
Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments

Aug 1, 2023 | rmdopen.bmj.com | Kimito Kawahata |Tomonori Ishii |Takahisa Gono |Yumi Tsuchiya

DiscussionThe present study assessed the efficacy of UST in Japanese participants with active PM/DM despite treatment with one or more standard-of-care treatments.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →